Alembic
Alembic Limited, a prominent player in the pharmaceutical and biotechnology industry, is headquartered in Vadodara, India. Founded in 1907, the company has established itself as a leader in the development and manufacturing of active pharmaceutical ingredients (APIs) and formulations. With a strong presence in both domestic and international markets, Alembic serves a diverse clientele across various therapeutic segments. The company is renowned for its commitment to quality and innovation, offering a wide range of products that include generic and branded formulations. Alembic's state-of-the-art facilities and adherence to stringent regulatory standards set it apart in a competitive landscape. Over the years, Alembic has achieved significant milestones, including successful collaborations and a robust pipeline of new drug applications, solidifying its position as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Alembic's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alembic's score of 17 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alembic's reported carbon emissions
In 2023, Alembic reported carbon emissions of approximately 3,220 kg CO2e for Scope 1 in India. This marks a reduction from 4,520 kg CO2e in 2022, demonstrating a commitment to lowering direct emissions. On a global scale, Alembic's emissions for 2023 included about 6,809,000,000 kg CO2e for Scope 1, 8,550,000,000 kg CO2e for Scope 2, and 476,792,000 kg CO2e for Scope 3. Looking ahead, Alembic has not specified any formal reduction targets or climate pledges, indicating a potential area for future commitment. The company’s emissions data reflects its operational impact and highlights the importance of ongoing efforts to enhance sustainability practices within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 6,809,000,000 | 0,000,000,000 |
| Scope 2 | 8,550,000,000 | 0,000,000,000 |
| Scope 3 | 476,792,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alembic is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
